{"id":"https://openalex.org/W2467783240","doi":null,"title":"[Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].","display_name":"[Multicenter phase II study of pre-administered uracil/tegafur (UFT) plus gemcitabine for unresectable/recurrent pancreatic cancer].","publication_year":2011,"publication_date":"2011-05-01","ids":{"openalex":"https://openalex.org/W2467783240","mag":"2467783240","pmid":"https://pubmed.ncbi.nlm.nih.gov/21566438"},"language":"ja","primary_location":{"id":"pmid:21566438","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21566438","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"Clinical Trial, Phase II"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014204252","display_name":"Shoji Nakamori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Shoji Nakamori","raw_affiliation_strings":["Pancreatic Cancer Study Group, Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pancreatic Cancer Study Group, Dept. of Gastroenterological Surgery, Graduate School of Medicine, Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039293087","display_name":"Wakio Endo","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Wakio Endo","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010348565","display_name":"Hiroki Ozato","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Hiroki Ozato","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080006264","display_name":"Takashi Shibata","orcid":"https://orcid.org/0000-0002-6459-5440","observed_orcids":["https://orcid.org/0000-0002-6459-5440"]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takashi Shibata","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023602886","display_name":"Yutaka Takeda","orcid":"https://orcid.org/0000-0002-7981-2487","observed_orcids":["https://orcid.org/0000-0002-7981-2487"]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yutaka Takeda","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011464047","display_name":"Ken Tohno","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ken Tohno","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074827271","display_name":"Yasunori Hasuike","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yasunori Hasuike","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113773295","display_name":"Seizo Masutani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Seizo Masutani","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5055151557","display_name":"Takashi Morimoto","orcid":"https://orcid.org/0000-0002-6428-5274","observed_orcids":["https://orcid.org/0000-0002-6428-5274"]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takashi Morimoto","raw_affiliation_strings":["Osaka University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113595758","display_name":"Yuichirou Doki","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yuichirou Doki","raw_affiliation_strings":["Osaka -University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka -University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111584585","display_name":"Masaki Mori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masaki Mori","raw_affiliation_strings":["Osaka -University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka -University","institution_ids":["https://openalex.org/I98285908"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5108403721","display_name":"Morito Monden","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I98285908","display_name":"The University of Osaka","ror":"https://ror.org/035t8zc32","country_code":"JP","type":"education","lineage":["https://openalex.org/I98285908"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Morito Monden","raw_affiliation_strings":["Osaka -University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Osaka -University","institution_ids":["https://openalex.org/I98285908"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I98285908"],"apc_list":null,"apc_paid":null,"fwci":0.4454,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.67769843,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":96},"biblio":{"volume":"38","issue":"5","first_page":"789","last_page":"92"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10231","display_name":"Pancreatic and Hepatic Oncology Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10760","display_name":"Pancreatitis Pathology and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tegafur-uracil","display_name":"tegafur-uracil","score":0.9120000004768372},{"id":"https://openalex.org/keywords/gemcitabine","display_name":"gemcitabine","score":0.9900000095367432},{"id":"https://openalex.org/keywords/unresectable-pancreatic-cancer","display_name":"unresectable pancreatic cancer","score":0.843999981880188},{"id":"https://openalex.org/keywords/recurrent-pancreatic-cancer","display_name":"recurrent pancreatic cancer","score":1.0},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6230000257492065},{"id":"https://openalex.org/keywords/outpatient-chemotherapy","display_name":"outpatient chemotherapy","score":0.6549999713897705},{"id":"https://openalex.org/keywords/5-fluorouracil-prodrug","display_name":"5-fluorouracil prodrug","score":0.9210000038146973},{"id":"https://openalex.org/keywords/treatment-related-toxicity","display_name":"treatment toxicity","score":0.5170000195503235},{"id":"https://openalex.org/keywords/survival","display_name":"survival","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C2777299880","wikidata":"https://www.wikidata.org/wiki/Q413370","display_name":"Tegafur","level":3,"score":0.9047459363937378},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8847090601921082},{"id":"https://openalex.org/C2780258809","wikidata":"https://www.wikidata.org/wiki/Q414143","display_name":"Gemcitabine","level":3,"score":0.7650250196456909},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6968489289283752},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.6935603022575378},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6657512187957764},{"id":"https://openalex.org/C2780210213","wikidata":"https://www.wikidata.org/wiki/Q212961","display_name":"Pancreatic cancer","level":3,"score":0.5382070541381836},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.5098142027854919},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.5005252361297607},{"id":"https://openalex.org/C3020110884","wikidata":"https://www.wikidata.org/wiki/Q695416","display_name":"Outpatient clinic","level":2,"score":0.45598605275154114},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.409214586019516},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3333737254142761}],"mesh":[{"descriptor_ui":"D000093542","descriptor_name":"Gemcitabine","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D003841","descriptor_name":"Deoxycytidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005641","descriptor_name":"Tegafur","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D005641","descriptor_name":"Tegafur","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D010190","descriptor_name":"Pancreatic Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D014498","descriptor_name":"Uracil","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D014498","descriptor_name":"Uracil","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:21566438","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21566438","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Gan to kagaku ryoho. Cancer & chemotherapy","raw_type":"Clinical Trial, Phase II"},{"id":"mag:2467783240","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21566438","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2260843134","https://openalex.org/W2070780256","https://openalex.org/W2988689375","https://openalex.org/W1985541721","https://openalex.org/W2415776144","https://openalex.org/W2255728954","https://openalex.org/W1965246454","https://openalex.org/W2412662850","https://openalex.org/W1965040871","https://openalex.org/W2075356897"],"abstract_inverted_index":{"Our":[0],"objective":[1],"was":[2,32,52,110],"to":[3],"evaluate":[4],"the":[5,10,27,70,149],"efficacy":[6],"and":[7,18,41,47,57,99,127],"toxicity":[8],"of":[9,12,16,69],"pre-administration":[11],"UFT":[13,30,137],"(uracil/tegafur:":[14],"prodrug":[15],"5-FU)":[17],"GEM":[19,48],"combination":[20],"therapy":[21],"for":[22,144],"unresectable/recurrent":[23,145],"pancreatic":[24,146],"cancer":[25,147],"in":[26,148],"outpatient":[28,150],"setting.":[29,151],"(250mg/m(2)/day)":[31],"orally":[33],"administered":[34,53],"from":[35,42],"day":[36,39,43,55],"1":[37],"through":[38,45],"6":[40,100],"8":[44,89],"13,":[46],"(800mg/m(2),":[49],"div/30":[50],"min)":[51],"on":[54,67],"7":[56],"14,":[58],"with":[59],"a":[60,104,141],"one-week":[61],"rest":[62],"every":[63],"3":[64,118],"weeks":[65],"based":[66],"results":[68],"previous":[71],"phase":[72],"I":[73],"study.":[74],"Thirty-six":[75],"pts":[76,94,101],"(24":[77],"male,":[78],"12":[79],"female)":[80],"were":[81,88,120,131],"enrolled":[82],"(median":[83],"age,":[84],"63.8":[85],"yrs).":[86],"There":[87,130],"partial":[90],"responses":[91],"(25%).":[92],"Eighteen":[93],"(56%)":[95],"had":[96,103],"stable":[97],"disease,":[98],"(19%)":[102],"progression.":[105],"The":[106],"median":[107],"survival":[108],"time":[109],"7.":[111],"0":[112],"months(":[113],"range":[114],"1.5":[115],"-66).":[116],"Grade":[117,133],"toxicities":[119],"leucopenia":[121],"(17%),":[122],"thrombocytopenia":[123],"(3%),":[124,126],"nausea":[125],"liver":[128],"dysfunctions(3%).":[129],"no":[132],"4":[134],"toxicities.":[135],"Pre-administered":[136],"plus":[138],"GM":[139],"is":[140],"promising":[142],"treatment":[143]},"counts_by_year":[{"year":2014,"cited_by_count":1},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-02T09:45:03.842371","created_date":"2016-07-22T00:00:00"}